AI Generated Image
High medicine prices are not only a budget problem; they can determine whether clinics stock essential treatments and whether families complete a course of care. BRICS generic medicine coalitions bring together manufacturing capacity, public-health diplomacy, regulatory cooperation and pooled demand to make affordable medicines more accessible across the developing world. The idea is not to eliminate pharmaceutical innovation, but to rebalance the system so patents do not become permanent barriers to treatment.
How Do BRICS Generic Medicine Coalitions Lower Healthcare Costs?
BRICS generic medicine coalitions lower costs by increasing competition, expanding reliable supply, and giving developing countries more leverage in procurement and intellectual property negotiations. Generic medicines usually cost less than brand-name equivalents because manufacturers do not have to repeat the original discovery and clinical development process. Competition among qualified suppliers can push prices down further. The World Health Organisation also links quality-assured generics and biosimilars with lower-priced alternatives to brand-name products, which is why access policies often focus on safe generic entry rather than price controls alone.
In practice, the BRICS approach matters because several members have large pharmaceutical markets, manufacturing bases or public-sector health systems that can shape demand. The BRICS platform has expanded beyond its original five members and now comprises eleven countries, including major developing-world economies with different strengths in production, regulation, research and procurement. When these capabilities are coordinated, countries that struggle to negotiate alone can gain access to more suppliers, shared technical knowledge and stronger political backing for public-health flexibilities.
Patent Monopolies and the Access Gap
Patents are designed to reward innovation by giving inventors a temporary exclusive right. In pharmaceuticals, that exclusivity can help fund research, but it can also keep prices high when there are no therapeutic alternatives, no negotiated licence or no affordable generic version available. For low- and middle-income countries, the pressure is especially intense because public budgets are limited and patients often pay high out-of-pocket costs.
The central problem is not simply that patents exist. It is that the patent system can become difficult to navigate when public-health needs are urgent, domestic manufacturing is weak or governments lack bargaining power. A single country may know it needs a lower-cost medicine, yet still face legal uncertainty, supply shortages, technical barriers or fears of trade pressure.
That is where pharmaceutical collaboration becomes practical. A coalition can identify shared medicine needs, map patent barriers, compare regulatory requirements and approach manufacturers with a larger, clearer market. Instead of each country acting as a small, isolated buyer, aligned countries can create a more predictable demand signal.
The Policy Tools Behind Affordable Medicines
The international trade system already recognises that intellectual property rules must be interpreted alongside public-health needs. The WTO’s Doha Declaration confirmed that the TRIPS Agreement should not prevent members from taking measures to protect public health, including using flexibilities such as compulsory licensing. The later TRIPS amendment created a legal pathway for low-cost generic medicines to be produced and exported under a compulsory licence for countries that lack sufficient manufacturing capacity.
These tools are powerful, but they are not automatic. Governments must know when to use them, have domestic laws in place, identify qualified manufacturers and manage procurement. The WTO has noted that pooling demand, improving regulatory compatibility and using the export compulsory licensing system as part of broader local-production strategies can help make the mechanism more commercially sustainable and practical.
Key policy levers include:
- Compulsory licensing: A government authorises the production or import of a patented medicine without the patent holder’s consent, usually with conditions and remuneration.
- Voluntary licensing: Patent holders allow selected manufacturers to produce generics, often for defined territories or markets.
- Pooled procurement: Multiple buyers combine demand to negotiate better terms and reduce uncertainty for suppliers.
- Regulatory reliance and harmonisation: Regulators reduce duplication by recognising trusted assessments or aligning technical standards.
- Local and regional production: Countries invest in manufacturing capacity so that supply is not entirely dependent on distant exporters.
- Quality assurance: Governments prioritise medicines that meet recognised safety, efficacy and manufacturing standards, preventing low prices from becoming synonymous with low trust.
Together, these levers show why affordable medicines require more than a factory. They require legal preparedness, transparent procurement, reliable quality systems and coordinated demand.
Why Is BRICS Positioned to Influence Generic Medicine Access?
BRICS is positioned to influence access because it combines large patient populations, emerging-market manufacturing capacity and a political forum focused on Global South cooperation. BRICS health declarations have repeatedly emphasised access to safe, effective, quality and affordable medicines, including generics, while also supporting cooperation on regulation, research, vaccines, diagnostics and broader health systems.
India is often discussed as a major source of generic medicine production. China has scale in active pharmaceutical ingredients and manufacturing ecosystems, while Brazil and South Africa have long histories in public-health access debates. Newer BRICS members also add regional reach and demand. The point is not that every BRICS country plays the same role. The opportunity comes from their complementary strengths.
A practical coalition might work like this: Health Ministries identify a medicine that is clinically important but unaffordable; patent experts assess legal options; regulators define quality requirements; and procurement agencies aggregate demand across participating countries. Manufacturers then have a clearer commercial case for production, while governments can negotiate from a stronger position.
This matters for diseases where treatment continuity is essential. HIV, tuberculosis, cancer, diabetes, cardiovascular disease and antimicrobial resistance all create long-term medicine needs. If a country cannot secure stable prices and reliable supply, clinical guidelines become promises the system cannot keep.
Pharmaceutical Collaboration Turns Scale Into Savings
Scale is one of the quiet forces behind lower medicine prices. A manufacturer is more likely to invest in production, registration, packaging and distribution when demand is predictable. A health system is more likely to negotiate confidently when it can compare suppliers and avoid last-minute emergency purchasing.
BRICS generic medicine coalitions can create savings through several channels:
- More suppliers enter the market: When qualified generic manufacturers compete, buyers gain alternatives and brand-name monopoly pricing weakens.
- Procurement becomes less fragmented: Shared demand can reduce duplicated tenders and improve negotiating power.
- Regulators share knowledge: Technical cooperation can shorten avoidable delays while maintaining safety and quality.
- Supply chains become more resilient: Regional production and diversified sourcing reduce dependence on a single supplier or route.
- Public-health flexibilities become more usable: Countries are more likely to act when legal, technical and diplomatic support is available.
The benefits are not only financial. Lower prices can help governments expand formularies, keep clinics stocked and reduce the risk that patients stop treatment because of cost. In public-health terms, affordability is part of effectiveness: a medicine that people cannot obtain does not improve outcomes.
Quality, Trust and Regulation Cannot Be Afterthoughts
Low-cost medicines only help when patients and clinicians trust them. That makes quality assurance central to any BRICS pharmaceutical collaboration. If a coalition focuses only on price, it risks counterfeit products, weak pharmacovigilance, poor manufacturing oversight and public scepticism.
WHO prequalification and strong national regulatory authorities are important because they support confidence in quality-assured medicines. WHO notes that medicine prequalification has stimulated price competition and helped available funds treat more patients in areas such as HIV/AIDS, tuberculosis and malaria. For developing countries, this combination of affordability and quality is the real target.
A strong coalition should therefore include:
- Clear product specifications and bioequivalence standards.
- Transparent supplier qualification.
- Shared inspection or reliance mechanisms where appropriate.
- Post-market surveillance for safety and product quality.
- Regional systems to report shortages and adverse events.
- Procurement rules that reward reliability, not just the lowest bid.
This is also where public communication matters. Patients may hear ‘generic’ and assume ‘inferior’. Governments, doctors, pharmacists and civil society groups need to explain that quality-assured generics are evaluated against defined standards and can serve the same clinical purpose at a lower cost.
The Limits and Risks of Coalition-Based Access
BRICS cooperation is promising, but it is not a simple cure for high medicine prices. Patent landscapes can be complicated, and some newer therapies involve biologics, data exclusivity, trade secrets, complex manufacturing or device-drug combinations. Even when legal access is possible, production may require technology transfer, specialised equipment, skilled workers and reliable inputs.
Geopolitics can also interfere. BRICS members do not always have identical interests, and suppliers may face sanctions, currency risks, shipping constraints or regulatory differences. A coalition that looks strong politically can still struggle operationally if procurement agencies cannot align timelines or payment systems.
There is also a legitimate concern about innovation incentives. The best access strategy should distinguish between blocking abusive monopoly practices and undermining the research ecosystem that produces new treatments. A balanced model supports innovation while ensuring that public-health emergencies, essential medicines and neglected diseases are not held hostage by unaffordable pricing.
A Practical Path for Developing Countries
For governments and health advocates, the most useful question is not whether patents or generics are ‘good’ or ‘bad’. The better question is how to build a system that rewards genuine innovation while ensuring essential treatments reach people.
A practical access agenda could include:
- Map priority medicines where price, patents or shortages restrict treatment.
- Update national laws so TRIPS flexibilities are usable before a crisis.
- Join regional or BRICS-aligned procurement initiatives where demand overlaps.
- Invest in regulatory capacity, quality testing and pharmacovigilance.
- Support local production where it is economically and technically realistic.
- Encourage voluntary licensing and technology transfer when they deliver broad access.
- Use compulsory licensing when public-health needs justify it and other routes fail.
- Publish procurement data to improve transparency and accountability.
The strongest coalitions will be practical rather than symbolic. They will connect Ministers, regulators, manufacturers, clinicians, patient groups and financing institutions around specific medicines and measurable access barriers.
The Takeaway
Breaking patent monopolies does not mean rejecting pharmaceutical innovation. It means refusing to treat exclusivity as more important than human life, especially when legal tools and manufacturing capacity can deliver safe, affordable medicines.
BRICS generic medicine coalitions can help developing countries move from isolated price negotiations to coordinated pharmaceutical collaboration. When they combine quality assurance, pooled demand, regulatory cooperation and the smart use of public-health flexibilities, they can lower healthcare costs while making medicine access more stable, fair and resilient.
Also Read: Skip The West: How BRICS Network University Is Creating New Research Options For Indian Students
To read more such news, download Bharat Express news apps
